Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection
Evaluate the Efficacy and Safety of TG-2349 in Combination With Peg-interferon and Ribavirin in Treatment naïve East Asian Subjects With Chronic Hepatitis C Virus Genotype 1b Infection.
Sponsor: TaiGen Biotechnology Co., Ltd.
Listed as NCT02340962, this PHASE2 trial focuses on Hepatitis C, Chronic and remains completed. Sponsored by TaiGen Biotechnology Co., Ltd., it has been updated 10 times since 2015, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Aug 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Aug 2023 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Nov 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Nov 2018 [monthly]
Completed PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
May 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- TaiGen Biotechnology Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Kaohsiung City, Taiwan